Incyte (Nasdaq:INCY) announces it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales milestones, for total potential consideration of up to $2.0 billion subject to customary closing adjustments. The proposed acquisition would add VGA039, a novel monoclonal antibody, to Incyte’s hematology portfolio. Vega Therapeutics’ lead candidate, VGA039, modulates Protein S to improve hemostasis, potentially improving the body’s ability to control bleeding in numerous bleeding disorders.
Read the full article: Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Its Hematology Portfolio into Bleeding Disorders //
Source: https://www.businesswire.com/news/home/20260608789389/en/Incyte-to-Acquire-Vega-Therapeutics-a-Wholly-Owned-Subsidiary-of-Star-Therapeutics-Expanding-its-Hematology-Portfolio-into-Bleeding-Disorders